Navigation Links
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with PHN. Solace anticipates having results from the study in the second half of 2009.

SLC022 is an orally administered glial cell modulator that has shown efficacy in well-established preclinical pain models. Glial cells represent an important new target for the treatment of chronic pain based on their active role in neuronal pain signaling.

"The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain," said Dr. Eliot Forster, Solace's Chief Executive Officer. "Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound's previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile."

Solace's advancement of SLC022 caps a year of significant progress. In 2008, Solace expanded its glial cell modulator program by identifying next-generation, novel leads with attractive drug properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets.

Solace Pharmaceuticals also established a two-year collaboration with Professor Keith Channon, MD FRCP, of the Department of Cardiovascular Medicine at the University of Oxford, UK. Professor Channon is a world-leading expert in the biochemistry of the BH4 pathway and the vascular endothelial system. Dr. Channon's work complements Solace's work in the development of small-molecule inhibitors of the BH4 pathway for treating chronic pain.

"We believe that the collaboration between Professor Channon and Solace will significantly augment the understanding of GCH1 and help advance development of promising therapeutic compounds," said Dr. Al Naylor, Solace's Head of Research.

About Solace Pharmaceuticals

Solace Pharmaceuticals discovers and develops innovative treatments for pain. Solace's research and development programs are focused on exploiting novel biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit the company's website at http://www.solacepharma.com.

     Contact:

     Marie Lossky, PhD
     Director, Business Development and
     Intellectual Property
     Solace Pharmaceuticals
     Phone: 617 401 4006
     Email: mlossky@solacepharma.com

'/>"/>
SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
8. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Jeffrey Zucker , ... Trials, will present at this year,s Summit for Clinical Operations ... in Miami, FL. Zucker will discuss ... study execution, supporting SCOPE,s "Improving Site Study Activation and Performance" ... Thursday, Feb. 25 at 11:05 a.m. --> ...
(Date:2/11/2016)... , February 11, 2016 F ... answers at the ... a world-leading provider of scientific, technical and medical information products and services, ... to evidence-based, peer reviewed clinical information via a mobile device. Elsevier designed ... ClinicalKey for Nursing. The new app is available in Android ...
(Date:2/11/2016)... Feb. 11, 2016 Exactus Pharmacy Solutions, ... high-quality specialty pharmacy care for those suffering from ... has achieved full Specialty Pharmacy Accreditation from URAC, ... to promoting health care quality through accreditation, education ... --> The URAC accreditation process demonstrates a ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... In a new ... plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the ... recommendations for rhinoplasty surgeons when addressing this vital area. , The upper lateral ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, MD, DC ... surgeons to know in 2016 . The list consists of spine surgeons across the ... , Dr. Corenman understands the importance of clinical excellence; he has been awarded the ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment ... in support of a local boy named Barrett, who has been fighting ALL leukemia ... and rally support for, all local families dealing with childhood cancer. Information on how ...
(Date:2/11/2016)... ... February 11, 2016 , ... From ... American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center ... awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment options. ...
Breaking Medicine News(10 mins):